24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publication dates

Carcinoma Industry, December 2014 Market Reports from Top Publishers

You might be interested in: Cancer, Diagnostic, Neck Cancer, more »


 
1-10 of 72 reports for Carcinoma

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2014

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • December 2014
  • by Global Markets Direct

... Therapeutic landscape of gastroesophageal (ge) junction carcinomas- the report reviews key pipeline products under drug profile section which includes, product description, moa and r&d brief, licensing ...

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • December 2014
  • by Global Markets Direct

... For the indicated disease.Scope- the report provides a snapshot of the global therapeutic landscape of transitional cell carcinoma (urothelial cell carcinoma)- the report reviews key ...

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2014

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • November 2014
  • by Global Markets Direct

... Therapeutic landscape of basal cell carcinoma (basal cell epithelioma)- the report reviews key pipeline products under drug profile section which includes, product description, moa and r&d brief, licensing ...

Sunshine Biopharma, Inc. (Symbol:SBFM) SWOT Analysis, Strategy, Revenues and Profits

Sunshine Biopharma, Inc. (Symbol:SBFM) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Different types of multidrug resistant cancer cell lines including breast cancer, uterine carcinoma, pancreatic cancer and small-cell lung cancer. Sunshine biopharma also offers difluoro-etoposide, which ...

Tikcro Technologies, Ltd. (Symbol:TIKRF) SWOT Analysis, Strategy, Revenues and Profits

Tikcro Technologies, Ltd. (Symbol:TIKRF) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Phase ii/b clinical trials for the treatment of pancreatic cancer and for superficial bladder carcinoma cancer, as well as a phase i/iia clinical trial for the treatment of ovarian cancer. Tikcro ...

Hepatocellular Carcinoma - Pipeline Review, H2 2014

Hepatocellular Carcinoma - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • November 2014
  • by Global Markets Direct

... Of the hepatocellular carcinoma pipeline on the basis of target, moa, route of administration and molecule type- latest news and deals relating related to pipeline productsreasons to buy ...

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • November 2014
  • by Global Markets Direct

... A snapshot of the global therapeutic landscape of adrenocortical carcinoma (adrenal cortex cancer)- the report reviews key pipeline products under drug profile section which includes, product description ...

Squamous Cell Carcinoma - Pipeline Review, H2 2014

Squamous Cell Carcinoma - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • October 2014
  • by Global Markets Direct

... Of development ranging from pre-registration till discovery and undisclosed stages- a detailed assessment of monotherapy and combination therapy pipeline projects- coverage of the squamous cell carcinoma ...

EpiCast Report: Cushing's Syndrome - Epidemiology Forecast to 2023

EpiCast Report: Cushing's Syndrome - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

... Epidemiological forecast for the diagnosed prevalent cases of cs, cushing's disease, ectopic- adrenocorticotropic hormone (acth) cs, adrenal adenoma cs, and adrenal carcinoma cs segmented by age (18 to =85 years ...

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014, Global Markets Direct

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014, Global Markets Direct

  • $ 2 000
  • Industry report
  • September 2014
  • by Global Markets Direct

... Therapeutic landscape of metastatic hepatocellular carcinoma (hcc)- the report reviews key pipeline products under drug profile section which includes, product description, moa and r&d brief, licensing ...

About 1 500 reports for Carcinoma

Download Unlimited Documents from Trusted Public Sources

Pathology Description in Italy

  • February 2013
    61 pages
  • Pathology  

    Digestive Syste  

  • Italy  

View report >

11 Companies for Carcinoma

Read our Company Profiles

Novartis Inc.

Switzerland

Amgen Inc.

United States

Eli Lilly and Co.

United States

Pfizer Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.